Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 12;20(1):27.
doi: 10.1186/s10194-019-0979-y.

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?

Valentina Favoni  1   2 , Luca Giani  3 , Linda Al-Hassany  4 , Gian Maria Asioli  5   6 , Calogera Butera  7 , Irene de Boer  8 , Martina Guglielmetti  9   10   11 , Chrysoula Koniari  12 , Theodoros Mavridis  12 , Marge Vaikjärv  13 , Iris Verhagen  4   8 , Angela Verzina  14   15 , Bart Zick  4   8 , Paolo Martelletti  9   10 , Simona Sacco  16   17 ; European Headache Federation School of Advanced Studies (EHF-SAS)
Affiliations
Review

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?

Valentina Favoni et al. J Headache Pain. .

Abstract

Calcitonin gene-related peptide (CGRP) is a neuropeptide with a pivotal role in the pathophysiology of migraine. Blockade of CGRP is a new therapeutic target for patients with migraine. CGRP and its receptors are distributed not only in the central and peripheral nervous system but also in the cardiovascular system, both in blood vessels and in the heart. We reviewed the current evidence on the role of CGRP in the cardiovascular system in order to understand the possible short- and long-term effect of CGRP blockade with monoclonal antibodies in migraineurs.In physiological conditions, CGRP has important vasodilating effects and is thought to protect organs from ischemia. Despite the aforementioned cardiovascular implication, preventive treatment with CGRP antibodies has shown no relevant cardiovascular side effects. Results from long-term trials and from real life are now needed.

Keywords: CGRP; CGRP antibody; Cardiovascular; Migraine treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests related to the content of the manuscript.

References

    1. Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain. 2013;14:1. doi: 10.1186/1129-2377-14-1. - DOI - PMC - PubMed
    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259. doi: 10.1016/S0140-6736(17)32154-2. - DOI - PMC - PubMed
    1. Edvinsson L. The Trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47–55. doi: 10.1111/head.13081. - DOI - PubMed
    1. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–350. doi: 10.1038/s41582-018-0003-1. - DOI - PubMed
    1. Edvinsson L, Tfelt-Hansen P. The blood-brain barrier in migraine treatment. Cephalalgia. 2008;28(12):1245–1258. doi: 10.1111/j.1468-2982.2008.01675.x. - DOI - PubMed

MeSH terms

Substances